Biomarkers of skin and lung fibrosis in systemic sclerosis

References

• Abraham DJ, Krieg T, Distler J, et al. Overview of pathogenesis of systemic sclerosis. Rheumatology. 2009;48(3):3–7.
   Google Scholar
• Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557–567.
   PubMed Web of Science ®Google Scholar
• Nietert PJ, Silver RM. Systemic sclerosis: environmental and occupational risk factors. Curr Opin Rheumatol. 2000;12:520–526.
   PubMed Web of Science ®Google Scholar
• CM B, KI W. Genetics of scleroderma. Clin Dermatol. 1994;12:337–347.
   PubMed Web of Science ®Google Scholar
• Gourh P, Arnett FC, Assassi S, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subset and clinical manifestations. Arthritis Res Ther. 2009;11:R147.
   PubMed Web of Science ®Google Scholar
• Kuwana M. Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting. J Nippon Med Sch. 2017;84(2):56–63.
   PubMed Web of Science ®Google Scholar
• Dick T, Mierau R, Bartz-Bazzanella P, et al. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis. Ann Rheum Dis. 2002;61:121–127.
   PubMed Web of Science ®Google Scholar
• •Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35:35–42.
   PubMed Web of Science ®Google Scholar
• Wucherpfennig KW. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest. 2001;108:1097–1104.
   PubMed Web of Science ®Google Scholar
• Manetti M, Matucci-Cerinic M. The new frontier in systemic sclerosis: from epigenetics to new treatments. Rheumatology. 2015;54:1757–1758.
   PubMed Web of Science ®Google Scholar
• Van Den Hoogen F, Khanna D, Fransen J, et al. classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013;2013(65):2737–2747.
   Google Scholar
• Henes J, Glaeser L, Kötter I, et al. Analysis of anti-topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation. Rheumatology (Oxford). 2017 Mar 1;56(3):451–456.
   PubMed Web of Science ®Google Scholar
• Rothfield N, Kurtzman S, Vazques-Abad D, et al. Association of anti-topoisomerase I with cancer. Arthritis Rheum. 1992;35:724.
   PubMedGoogle Scholar
• Distler O, Allanore Y, Denton CP, et al. Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2018;57(5):813–817.
   PubMed Web of Science ®Google Scholar
• Krieg T, Takehara K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford). 2009;48(3):14–18.
   Google Scholar
• Steen V, Denton CP, Pope JE, et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford). 2009;48(3):19–24.
   Google Scholar
• Hughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology (Oxford). 2017;56(1):14–25.
   PubMed Web of Science ®Google Scholar
• Horimoto AMC, de Souza AS, Rodrigues SH, et al. Risk of digital ulcers occurrence in systemic sclerosis: a cross-sectional study. Adv Rheumatol. 2019;59(1):14.
   PubMedGoogle Scholar
• Khanna D, Seibold J, Goldin J, et al. Interstitial lung disease points to consider for clinical trials in systemic sclerosis. Rheumatology (Oxford). 2017;56(5):v27–v32.
   PubMedGoogle Scholar
• Denton CP, Wells AU, Coghlan JG. Major lung complications of systemic sclerosis. Nat Rev Rheumatol. 2018;14(9):511–527.
   PubMed Web of Science ®Google Scholar
• •Affandi AJ, Radstake TR, Marut W. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment. Semin Immunopathol. 2015;37(5):475–487.
   PubMed Web of Science ®Google Scholar
• Hasegawa M. Biomarkers in systemic sclerosis: their potential to predict clinical courses. J Dermatol. 2016;43(1):29–38.
   PubMed Web of Science ®Google Scholar
• Robinson WH, Lindstrom TM, Cheung RK, et al. Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol. 2013;9:267–276.
   PubMed Web of Science ®Google Scholar
• Castelino FV, Varga J. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. Expert Rev Clin Immunol. 2013;9:1077–1090.
   PubMed Web of Science ®Google Scholar
• Castro SV, Jimenez SA. Biomarkers in systemic sclerosis. Biomark Med. 2010;4(1):133–147.
   PubMed Web of Science ®Google Scholar
• McCoy SS, Reed TJ, Berthier CC, et al. Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta. Rheumatology (Oxford). 2017;56(11):1970–1981.
   PubMed Web of Science ®Google Scholar
• Abignano G, Blagojevic J, Bissell L-A, et al. European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. Rheumatology (Oxford). 2019;58(2):254–259.
   PubMed Web of Science ®Google Scholar
• Brkic Z, van Bon L, Cossu M, et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis. 2016;75:1567–1573.
   PubMed Web of Science ®Google Scholar
• De Lauretis A, Sestini P, Pantelidis P, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40:435–446.
   PubMed Web of Science ®Google Scholar
• Kayser C, Fritzler MJ. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol. 2015;6:167.
   PubMed Web of Science ®Google Scholar
• KT H, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther. 2003;5(2):80–93.
   PubMed Web of Science ®Google Scholar
• Graf SW, Hakendorf P, Lester S, et al. South Australian scleroderma register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis. 2012 Feb;15(1):102–109.
   PubMed Web of Science ®Google Scholar
• Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem. 1979;254:10514–10522.
   PubMed Web of Science ®Google Scholar
• Hesselstrand R, Scheja A, Shen GQ, et al. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology. 2003;42:534–540.
   PubMed Web of Science ®Google Scholar
• Colaci M, Giuggioli D, Sebastiani M, et al. Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. Autoimmun Rev. 2013;12(3):374–379.
   PubMed Web of Science ®Google Scholar
• Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol. 2004;16:723–732.
   PubMed Web of Science ®Google Scholar
• Moroi Y, Peebles C, Fritzler MJ, et al. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci. 1980;77:1627–1631.
   PubMed Web of Science ®Google Scholar
• Tramposch HD, Smith CD, Senecal JL, et al. A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum. 1984;27:121–124.
   PubMedGoogle Scholar
• Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988;31:196–203.
   PubMed Web of Science ®Google Scholar
• Hudson M, Mahler M, Pope J, et al. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol. 2012;39(4):787–794.
   PubMed Web of Science ®Google Scholar
• Maddison PJ. Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol. 2000;14(1):111–124.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Lucas M, Fertig N, et al. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum. 2009;60(4):1112–1118.
   PubMedGoogle Scholar
• Fertig N, Domsic RT, Rodriguez-Reyna T, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum. 2009;61(7):958–965.
   PubMedGoogle Scholar
• Okano Y, Steen VD, Medsger TA. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med. 1993;119(10):1005–1101.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kodera M, Matsushita T, et al. Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol. 2015;67(4):1045–1052.
   PubMed Web of Science ®Google Scholar
• Lazzaroni M-G, Cavazzana I, Colombo E, et al. Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening. J Rheumatol. 2017;44:639–647.
   PubMed Web of Science ®Google Scholar
• Mihai C, Tervaert JW. Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis. 2010;69(2):319–324.
   PubMed Web of Science ®Google Scholar
• Lewandowska K, Ciurzynski M, Gorska E, et al. Antiendothelial cells antibodies in patients with systemic sclerosis in relation to pulmonary hypertension and lung fibrosis. Adv Exp Med Biol. 2013;756:147–153.
   PubMed Web of Science ®Google Scholar
• Sunderkötter C, Riemekasten G. Pathophysiology and clinical consequences of Raynaud’s phenomenon related to systemic sclerosis. Rheumatology (Oxford). 2006;45:33–35.
   Web of Science ®Google Scholar
• Avouac J, Toniolo E, Lepri G, et al. Sensitivity to change of nailfold videocapillaroscopy and relationship with disease progression. Poster session presented at: Systemic sclerosis, fibrosing syndromes and Raynauds - clinical aspects and therapeutics. 2015 ACR/ARHP Annual Meeting; 2015 Nov 6 - 11; San Francisco, CA.
   Google Scholar
• Lambova S, Müller-Ladner U. Capillaroscopic findings in systemic sclerosis – are they associated with disease duration and presence of digital ulcers? Discov Med. 2011;12(66):413–418.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol. 2010;6:578–587.
   PubMed Web of Science ®Google Scholar
• Dobrota R, Maurer B, Graf N, et al. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Ann Rheum Dis. 2016;75(10):1743–1748.
   PubMed Web of Science ®Google Scholar
• Kumánovics G, Péntek M, Bae S, et al. Assessment of skin involvement in systemic sclerosis. Rheumatology (Oxford). 2017;56(5):v53–v66.
   PubMedGoogle Scholar
• Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum. 2007;56:2422–2431.
   PubMed Web of Science ®Google Scholar
• Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22(7):1281–1285.
   PubMed Web of Science ®Google Scholar
• Iagnocco A, Kaloudi O, Perella C, et al. Ultrasound elastography assessment of skin involvement in systemic sclerosis: lights and shadows. J Rheumatol. 2010;37:1688–1691.
   PubMed Web of Science ®Google Scholar
• Wang L, Yan F, Yang Y, et al. Quantitative assessment of skin stiffness in localized scleroderma using ultrasound shear-wave elastography. Ultrasound Med Biol. 2017;43(7):1339–1347.
   PubMed Web of Science ®Google Scholar
• Abignano G, Aydin SZ, Castillo Gallego C, et al. Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma. Ann Rheum Dis. 2013;72(11):1845–1851.
   PubMed Web of Science ®Google Scholar
• Babalola O, Mamalis A, Lev Tov H, et al. Optical coherence tomography (OCT) of collagen in normal skin and skin fibrosis. Arch Dermatol Res. 2014;306:1–9.
   PubMed Web of Science ®Google Scholar
• Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One. 2008;3:e2696.
   PubMed Web of Science ®Google Scholar
• Farina G, Lafyatis D, Lemaire R, et al. A four gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2010;62:580–588.
   PubMed Web of Science ®Google Scholar
• Lakota K, Wei J, Carns M, et al. Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? Arthritis Res Ther. 2012;14(3):R102.
   PubMed Web of Science ®Google Scholar
• •Moon SJ, Bae JM, Park KS, et al. Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis. Ann Rheum Dis. 2019;78(6):817–825.
   PubMed Web of Science ®Google Scholar
• Rice LM, Mantero JC, Stifano G, et al. A proteome-derived longitudinal pharmacodynamic biomarker for diffuse systemic sclerosis skin. J Invest Dermatol. 2017;137(1):62–70.
   PubMed Web of Science ®Google Scholar
• Wei J, Fang F, Lam AP, et al. Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 2012;64:2734–2745.
   PubMed Web of Science ®Google Scholar
• Lafyatis R, Mantero JC, Gordon J, et al. Inhibition of β-catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: a randomized, double-blind, placebo-controlled trial of C-82. J Invest Dermatol. 2017 Dec;137(12):2473–2483.
   PubMed Web of Science ®Google Scholar
• Zhu H, Luo H, Zuo X. MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma. Exp Mol Med. 2013;45:e41.
   PubMed Web of Science ®Google Scholar
• Miao CG, Xiong YY, Yu H, et al. Critical roles of microRNAs in the pathogenesis of systemic sclerosis: new advances, challenges and potential directions. Int Immunopharmacol. 2015;28(1):626–633.
   PubMed Web of Science ®Google Scholar
• Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007;117(3):524–529.
   PubMed Web of Science ®Google Scholar
• ••Liakouli V, Cipriani P, Di Benedetto P, et al. The role of extracellular matrix components in angiogenesis and fibrosis: possible implication for Systemic Sclerosis. Mod Rheumatol. 2018;28(6):922–932.
   PubMed Web of Science ®Google Scholar
• Kim WU, Min SY, Cho ML, et al. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther. 2005;7(1):R71–9.
   PubMed Web of Science ®Google Scholar
• Manetti M, Guiducci S, Romano E, et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis. 2012;71(6):1064–1072.
   PubMed Web of Science ®Google Scholar
• Rimar D, Rosner I, Nov Y, et al. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Arthritis Rheumatol. 2014;66(3):726–730.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Asano Y, Akamata K, et al. Serum levels of ADAM12-S: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis. J Eur Acad Dermatol Venereol. 2013;27(6):747–753.
   PubMed Web of Science ®Google Scholar
• Rice LM, Padilla CM, McLaughlin SR, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 2015;125(7):2795–2807.
   PubMed Web of Science ®Google Scholar
• Wu M, Schneider DJ, Mayes MD, et al. Osteopontin in systemic sclerosis and its role in dermal fibrosis. J Invest Dermatol. 2012;132(6):1605–1614.
   PubMed Web of Science ®Google Scholar
• Barizzone N, Marchini M, Cappiello F, et al. Association of osteopontin regulatory polymorphisms with systemic sclerosis. Hum Immunol. 2011;72(10):930–934.
   PubMed Web of Science ®Google Scholar
• Le Gouellec N, Duhamel A, Perez T, et al. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. PLoS One. 2017;12(8):e0181692.
   PubMed Web of Science ®Google Scholar
• Orlandi M, Barsotti S, Lepri G, et al. One year in review 2018: systemic sclerosis. Clin Exp Rheumatol. 2018;36(Suppl 113(4)):3–23.
   PubMed Web of Science ®Google Scholar
• Highland KB, Garin MC, Brown KK. The spectrum of scleroderma lung disease. Semin Respir Crit Care Med. 2007;28(4):418–429.
   PubMed Web of Science ®Google Scholar
• Steen VD, Owens GR, Fino GJ, et al. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum. 1985;28(7):759–767.
   PubMedGoogle Scholar
• Olson AL, Brown KK, Fischer A. Connective tissue disease-associated lung disease. Immunol Allergy Clin North Am. 2012;32(4):513–536.
   PubMed Web of Science ®Google Scholar
• Schniering J, Guo L, Brunner M, et al. Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis. Arthritis Res Ther. 2018;20(1):183.
   PubMedGoogle Scholar
• •Schniering J, Benešová M, Brunner M, et al. Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2. Ann Rheum Dis. 2019;78(2):218–227.
   PubMed Web of Science ®Google Scholar
• Assassi S, Sharif R, Lasky RE, et al. GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther. 2010;12(5):R166.
   PubMed Web of Science ®Google Scholar
• Mitri GM, Lucas M, Fertig N, et al. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum. 2003;48(1):203–209.
   PubMedGoogle Scholar
• Ihn H, Sato S, Fujimoto M, et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol. 2000;119(1):203–209.
   PubMed Web of Science ®Google Scholar
• Baraut J, Michel L, Verrecchia F, et al. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev. 2010;10(2):65–73.
   PubMed Web of Science ®Google Scholar
• Lee CM, Park JW, Cho WK, et al. Modifiers of TGF-β1 effector function as novel therapeutic targets of pulmonary fibrosis. Korean J Intern Med. 2014;29(3):281–290.
   PubMed Web of Science ®Google Scholar
• Khanna D, Tashkin DP, Denton CP, et al. Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2019;58(4):567–579.
   PubMed Web of Science ®Google Scholar
• Obeidat M, Li X, Burgess S, et al. Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation. Eur Respir J. 2017;50:5.
   Web of Science ®Google Scholar
• Ohshimo S, Yokoyama A, Hattori N, et al. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun. 2005;338(4):1845–1852.
   PubMed Web of Science ®Google Scholar
• Bonella F, Volpe A, Caramaschi P, et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(1):27–33.
   PubMed Web of Science ®Google Scholar
• Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Scleroderma lung study research group. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009;36(4):773–780.
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL 6, surfactant protein A, surfactant protein D, and monocyte chemoattractant protein 1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165:378–381.
   PubMed Web of Science ®Google Scholar
• Yanaba K, Hasegawa M, Takehara K, et al. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol. 2004;31(6):1112–1120.
   PubMed Web of Science ®Google Scholar
• Hesselstrand R, Wildt M, Bozovic G, et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. Respir Med. 2013;107(7):1079–1086.
   PubMed Web of Science ®Google Scholar
• Minowa K, Nakiri Y, Lee S, et al. Examination of availability of the criteria for protective therapy against pneumocystis pneumonia. Nihon Rinsho Meneki Gakkai Kaishi. 2009;32:256–262.
   PubMedGoogle Scholar
• Hieshima K, Imai T, Baba M, et al. A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes. J Immunol. 1997;159(3):1140–1149.
   PubMed Web of Science ®Google Scholar
• Adema GJ, Hartgers F, Verstraten R, et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature. 1997;387(6634):713–717.
   PubMed Web of Science ®Google Scholar
• Prasse A, Pechkovsky DV, Toews GB, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum. 2007;56(5):1685–1693.
   PubMed Web of Science ®Google Scholar
• Cai M, Bonella F, He X, et al. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. Respir Med. 2013;107(9):1444–1452.
   PubMed Web of Science ®Google Scholar
• Kodera M, Hasegawa M, Komura K, et al. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 2005;52(9):2889–2896.
   PubMed Web of Science ®Google Scholar
• Zimmers TA, Jin X, Hsiao EC, et al. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock. 2005;23(6):543–548.
   PubMed Web of Science ®Google Scholar
• Yanaba K, Asano Y, Tada Y, et al. Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity. Mod Rheumatol. 2012;22(5):668–675.
   PubMed Web of Science ®Google Scholar
• Lambrecht S, Smith V, De Wilde K, et al. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. Arthritis Rheumatol. 2014;66(2):418–427.
   PubMed Web of Science ®Google Scholar
• Elhai M, Hoffmann-Vold AM, Avouac J, et al. Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2019;71: 972–982. [ Epub ahead of print].
   Web of Science ®Google Scholar
• Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016;11(10):e0163894.
   PubMed Web of Science ®Google Scholar
• Poudel DR, Jayakumar D, Danve A, et al. Determinants of mortality in systemic sclerosis: a focused review. Rheumatol Int. 2018;38(10):1847–1858.
   PubMed Web of Science ®Google Scholar
• Marasovic-Krstulovic D, Jurisic Z, Perkovic D, et al. Fulminant diffuse systemic sclerosis following aortic valve replacement. Med Hypotheses. 2014;82(6):792–794.
   PubMed Web of Science ®Google Scholar